Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

lations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to r
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
(Date:9/16/2014)... , Sept. 16, 2014 This report analyzes ... following Product Segments: Software, Hardware, and Biocontent. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ... seven-year historic analysis is provided for these markets. Market data ...
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
(Date:9/16/2014)... , Sept. 16, 2014  The Council ... entrepreneurial support organization in the country, today released ... Report . It showed that ... North Carolina startups in the technology, ... more global investment from a variety of sources. Significant ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... , SAN FRANCISCO, Nov. 17 Merriman ... lead placement agent in PolyMedix Inc.,s (OTC Bulletin Board: PYMX) ... units, which were priced at $1.00 per unit, consist of ... warrant to purchase 0.30 of a share of PolyMedix common ...
... , ... that a new market research report is available ... A Global Market Intelligence Report , ... a key discipline operating on the forefront of ...
... Hungary, Nov. 17 Hungarian drug producer Biropharma and ... connection American BioSciences Inc. and its partner Mate Hidvegi ... Avemar, a dietary supplement being used in cancer treatment ... two different sets of compounds hence the qualities of ...
Cached Biology Technology:Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 2Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 3Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 4Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 5Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 6Reportlinker Adds Bioinformatics - A Global Market Intelligence Report 7Hungarian Cancer Formula Producer Questions U.S. Introduction of AveUltra 2
(Date:9/16/2014)... the Exxon Valdez spilled 11 million gallons of oil ... up another giant oil spill in the Gulf of ... the Journal of Consumer Research , news coverage ... instead of catalyzing changes in the way fossil fuels ... media coverage of these two events helped to resolve ...
(Date:9/16/2014)... season of bounty. Fungi of dizzying variety erupt from ... search of elusive but delectable wild mushrooms. Part of ... hunt, and their mysterious not-quite-meat, not-quite-vegetable qualities that belie ... you are eating known to science? , The Fungi ... some estimates range up to 10 million species, only ...
(Date:9/15/2014)... INDIANAPOLIS -- Adding a common epilepsy drug to a ... fewer side effects. Moreover, the combination can reduce the ... to a team of pain researchers at Indiana University. ... patients with neuropathic pain, a difficult-to-treat condition often felt ... tissue damage. , "There is a huge unmet need ...
Breaking Biology News(10 mins):Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... crawls onto your lips while you sleep, drawn by the ... your blood. And if that,s not insult enough, it promptly ... Now Jean-Paul Paluzzi, a PhD candidate in biology ... to prevent the insects from leaving their messy calling card ...
... effective way of tackling global warming despite emitting small amounts ... Research led by the University of Edinburgh suggests that plant ... Earth,s emissions of methane which is considered to be about ... The results contrast with a previous scientific study which ...
... ANAHEIM, CA: Could organic labels lead you to overeat? ... organic snack has a lot fewer calories than it really ... Biology conference in Anaheim, Calif. They showed that people ... snack contained 40% fewer calories than the same cookies that ...
Cached Biology News:The kiss of death: Research targets lethal disease spread by insect that bites lips 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: